MX2013001237A - Compuestos inhibidores del virus de la hepatitis c. - Google Patents

Compuestos inhibidores del virus de la hepatitis c.

Info

Publication number
MX2013001237A
MX2013001237A MX2013001237A MX2013001237A MX2013001237A MX 2013001237 A MX2013001237 A MX 2013001237A MX 2013001237 A MX2013001237 A MX 2013001237A MX 2013001237 A MX2013001237 A MX 2013001237A MX 2013001237 A MX2013001237 A MX 2013001237A
Authority
MX
Mexico
Prior art keywords
hepatitis
virus inhibitors
compounds
virus
treatment
Prior art date
Application number
MX2013001237A
Other languages
English (en)
Other versions
MX337936B (es
Inventor
Jeffrey Lee Romine
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MX2013001237A publication Critical patent/MX2013001237A/es
Publication of MX337936B publication Critical patent/MX337936B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/204—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a compuestos, composiciones y métodos para el tratamiento de la infección del virus de la hepatitis C (HVC). También se describen composiciones farmacéuticas que contienen tales compuestos y métodos para usar estos compuestos en el tratamiento de la infección por HCV.
MX2013001237A 2010-08-04 2010-08-04 Compuestos inhibidores del virus de la hepatitis c. MX337936B (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2010/044356 WO2012018325A1 (en) 2010-08-04 2010-08-04 Hepatitis c virus inhibitors

Publications (2)

Publication Number Publication Date
MX2013001237A true MX2013001237A (es) 2013-05-28
MX337936B MX337936B (es) 2016-03-29

Family

ID=43640063

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013001237A MX337936B (es) 2010-08-04 2010-08-04 Compuestos inhibidores del virus de la hepatitis c.

Country Status (12)

Country Link
EP (1) EP2601188B1 (es)
JP (1) JP5596861B2 (es)
KR (1) KR20140045903A (es)
CN (1) CN103153986B (es)
AU (1) AU2010358561B2 (es)
BR (1) BR112013002729A2 (es)
CA (1) CA2807305A1 (es)
EA (1) EA022127B1 (es)
IL (1) IL224298A (es)
MX (1) MX337936B (es)
SG (1) SG187183A1 (es)
WO (1) WO2012018325A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8673954B2 (en) * 2009-02-27 2014-03-18 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
US9765087B2 (en) 2009-02-27 2017-09-19 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
CN102656160A (zh) 2009-07-16 2012-09-05 顶点制药公司 用于治疗或预防黄病毒感染的苯并咪唑类似物
JP2013522375A (ja) 2010-03-24 2013-06-13 バーテックス ファーマシューティカルズ インコーポレイテッド フラビウイルス感染を処置または予防するためのアナログ
BR112013004520A2 (pt) 2010-08-26 2016-06-07 Univ Emory inibidores potentes e seletivos do virus da hepatite c
US8552047B2 (en) 2011-02-07 2013-10-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9546160B2 (en) 2011-05-12 2017-01-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN103687489A (zh) 2011-05-18 2014-03-26 埃南塔制药公司 制备5-氮杂螺[2.4]庚烷-6-甲酸及其衍生物的方法
WO2013030750A1 (en) 2011-09-01 2013-03-07 Lupin Limited Antiviral compounds
US9326973B2 (en) 2012-01-13 2016-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
AU2013217224B2 (en) 2012-02-10 2017-04-06 Lupin Limited Antiviral compounds with a dibenzooxaheterocycle moiety
CA2869908C (en) * 2012-04-25 2018-02-20 Theravance Biopharma R&D Ip, Llc Hepatitis c virus inhibitors
US20150023913A1 (en) 2013-07-02 2015-01-22 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US9717712B2 (en) 2013-07-02 2017-08-01 Bristol-Myers Squibb Company Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
WO2015009744A1 (en) 2013-07-17 2015-01-22 Bristol-Myers Squibb Company Combinations comprising biphenyl derivatives for use in the treatment of hcv
US10617675B2 (en) 2015-08-06 2020-04-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JPWO2018212162A1 (ja) 2017-05-17 2020-03-19 株式会社トクヤマ ジアミノベンゼン化合物の製造方法
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
US20210246108A1 (en) 2018-06-28 2021-08-12 Tokuyama Corporation Method for Producing Alpha-Azidoaniline Derivative or Alpha,AlphaPrime-Diazide Derivative
IL286326B2 (en) 2019-03-15 2025-10-01 Medimmune Ltd Azatidobenzodiazepine dimers and conjugates containing them for use in the treatment of cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830905A (en) * 1996-03-29 1998-11-03 Viropharma Incorporated Compounds, compositions and methods for treatment of hepatitis C
US6448281B1 (en) * 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
AU2003264038A1 (en) 2002-08-12 2004-02-25 Bristol-Myers Squibb Company Combination pharmaceutical agents as inhibitors of hcv replication
WO2004026318A1 (ja) * 2002-09-20 2004-04-01 Kirin Beer Kabushiki Kaisha α-グリコシルセラミドを有効成分とするＣ型肝炎ウイルス抑制剤
WO2006093867A1 (en) 2005-02-28 2006-09-08 The Rockefeller University Structure of the hepatitits c virus ns5a protein
US8303944B2 (en) 2006-08-11 2012-11-06 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8147818B2 (en) * 2008-02-13 2012-04-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2010065681A1 (en) * 2008-12-03 2010-06-10 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
TWI438200B (zh) * 2009-02-17 2014-05-21 必治妥美雅史谷比公司 Ｃ型肝炎病毒抑制劑

Also Published As

Publication number Publication date
JP2013532725A (ja) 2013-08-19
EA022127B1 (ru) 2015-11-30
BR112013002729A2 (pt) 2016-05-31
WO2012018325A1 (en) 2012-02-09
CA2807305A1 (en) 2012-02-09
EP2601188A1 (en) 2013-06-12
AU2010358561A1 (en) 2013-03-21
KR20140045903A (ko) 2014-04-17
MX337936B (es) 2016-03-29
CN103153986A (zh) 2013-06-12
SG187183A1 (en) 2013-02-28
IL224298A (en) 2015-08-31
CN103153986B (zh) 2014-11-05
AU2010358561B2 (en) 2016-06-02
JP5596861B2 (ja) 2014-09-24
EA201370017A1 (ru) 2013-05-30
EP2601188B1 (en) 2017-10-18

Similar Documents

Publication Publication Date Title
MX2013001579A (es) Inhibidores del virus de la hepatitis c
TN2012000264A1 (en) Hepatitis c virus inhibitors
TN2012000214A1 (en) Hepatitis c virus inhibitors
MX2011008045A (es) Inhibidores del virus de la hepatitis c.
MY152971A (en) Hepatitis c virus inhibitors
MX337936B (es) Compuestos inhibidores del virus de la hepatitis c.
MX2010008749A (es) Inhibidores del virus de la hepatitis c.
PH12013501543A1 (en) Hepatitis c virus inhibitors
MX2010008531A (es) Derivados de bifenilo conformacionalmente restringido para uso como inhibidores del virus de la hepatitis c.
IL196815A0 (en) Hepatitis c virus inhibitors
PH12013502177A1 (en) Hepatitis c virus inhibitors
MX2010008699A (es) Derivados heterociclicos como inhibidores de virus de la hepatitis c.
MX2010008863A (es) Imidazolil-bifenil-imidazoles como inhibidores del virus de la hepatisis c.
ZA201005700B (en) Hepatitis c virus inhibitors
MX2012008221A (es) Inhibidores de virus flaviviridae.
MX2012008211A (es) Inhibidores de virus flaviviridae.
MX2012000959A (es) Inhibidores de los virus flaviviridae.
MX360452B (es) Inhibidores del virus de la hepatitis c.
MX2013004906A (es) Nuevos inhibidores especificos de la proteasa ns3 de hcv.
TN2013000335A1 (en) Hepatitis c virus inhibitors
TN2013000453A1 (en) Hepatitis c virus inhibitors
UA113048C2 (xx) Противірусні сполуки
TH149188A (th) สารยับยั้งไวรัสตับอักเสบ c
MY163245A (en) Hepatitis c virus inhibitors

Legal Events

Date Code Title Description
FG Grant or registration